FMP
NASDAQ
1.81 USD
0.0225 (1.24%)
Dr. Richard A. Miller M.D.
Healthcare
Biotechnology
https://www.corvuspharma.com
NASDAQ
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for p...
0001626971
US2210151005
221015100
863 Mitten Road
650 900 4520
US
28
Mar 23, 2016
0001626971
NASDAQ
Biotechnology
Healthcare
221015100
US2210151005
US
1.81
1.04
216.14k
88.88M
-
0.711-4.19
0.23
-
-
-
-
-3.24
-
https://www.corvuspharma.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.